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Purpose: Hereditary thrombophilia (HT) is a major risk factor for idiopathic pul-
monary embolism (iPE) and shows different prevalence among ethnic groups. The 
prevalence and clinical characteristics of HT in Korean patients with iPE were in-
vestigated. Materials and Methods: Patients with PE on computed tomography 
(CT) scan were recruited, and those with malignancy were excluded. Patients were 
divided into iPE and provoked PE (pPE) groups. The presence of HT in the iPE 
group was assessed by DNA sequencing of the corresponding gene in patients 
who had low levels of natural anticoagulants. The clinical characteristics of iPE 
with HT (iPE/HT+) were compared with those of iPE without HT (iPE/HT-) and 
pPE. Results: Out of 161 patients, 84 patients had iPE and 77 patients had pPE. 
Among 54 patients in the iPE group whose coagulation profiles were tested, 28 
patients were diagnosed with HT (51.9%; 28/54). Compared with the iPE/HT- and 
pPE groups, the iPE/HT+ group showed the highest proportion of male patients 
(71.4%; p<0.001); the youngest mean age (44±14 years; p<0.001); and the highest 
frequencies for history of venous thromboembolism (64.3%; p<0.001), concurrent 
deep vein thrombosis (75.0%; p=0.021), and adverse clinical outcomes (42.9%, 
p<0.001). Protein C deficiency was the most common HT. On molecular genetic 
tests, causative mutation was identified in 13 patients. Conclusion: In this study of 
Korean patients, about half of the patients with iPE had HT. Patients with iPE and 
HT were mostly young males with deep venous thrombosis (DVT), previous ve-
nous thromboembolism (VTE), and frequent adverse clinical outcomes. Therefore, 
Korean patients with iPE should be tested for HT.
Key Words:    Pulmonary embolism, hereditary thrombophilia, protein C deficien-
cy, Korea
INTRODUCTION
Venous thromboembolism (VTE) is a serious clinical condition that manifests as 
deep venous thrombosis (DVT), pulmonary embolism (PE), or both. PE has a high Mirae Lee, et al.
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This study was conducted to assess the prevalence of HT 
and its clinical implications in Korean patients with iPE. 
MATERIALS AND METHODS
　　　
Patient population
We retrospectively collected data from patients diagnosed 
with PE at Samsung Medical Center between October 2004 
and January 2009. The diagnosis of PE was based on multi-
detector computed tomography (CT) scans including indirect 
CT venography of the lower extremities. Exclusion criteria 
were an ethnic origin other than Korean and PE associated 
with malignancy. We divided the study patients into iPE and 
pPE groups. The pPE group comprised patients with PE 
and one or more acquired risk factor of PE (Table 1). All 
other patients were considered as having iPE. Concurrent 
DVT in the lower extremities was assessed by CT scan and 
indirect CT venography, with or without ultrasonography. 
HT was diagnosed based on coagulation tests. The clinical 
characteristics and adverse outcomes of iPE with HT (iPE/
HT+) group were compared with those of iPE without HT 
(iPE/HT-) and pPE groups. Adverse clinical outcomes were 
defined as death; cardiopulmonary resuscitation; thrombol-
ysis; surgical embolectomy; and use of percutaneous car-
diopulmonary support, inotropes, or mechanical ventila-
tion. The institutional review board of our institution 
approved this study.
Coagulation tests for thrombophilia
Coagulation tests to screen for thrombophilia at our center 
comprise global coagulation tests including prothrombin 
time, activated partial thromboplastin time (APTT), throm-
bin time, fibrinogen, PC activity (Stachrom® Protein C, Di-
agnostica Stago, Asnières, France), PS free antigen (Liatest® 
Free Protein S, Diagnostica Stago), AT activity (Stachrom® 
AT III, Diagnostica Stago), PLG activity (Stachrom® Plas-
minogen, Diagnostica Stago). Lupus anticoagulants (LA) 
were screened using APTT, LA sensitive PTT (PTT-LA), 
and dilute Russel veiper venom test on the STA®-Evolution 
Coagulation Analyzer. Reference ranges for the normal level 
of each anticoagulant were determined according to our in-
stitutional data.
Molecular genetic tests
The diagnosis of HT was also confirmed by molecular ge-
netic tests in available patients with low PC, PS, AT, and 
fatality rate of approximately 15%, exceeding the mortality 
rate of acute myocardial infarction.1 The likelihood of PE is 
substantially increased by well-known acquired risk factors 
and can be significantly reduced by prophylaxis.2 About 
half of PE cases, however, are idiopathic and occur without 
acquired risk factors such as antecedent trauma, surgery, 
immobilization, or diagnosis of cancer.3 Unlike provoked 
PE (pPE) with acquired risk factors, idiopathic PE (iPE) is 
less likely to be predicted or prevented.
Hereditary thrombophilia (HT) is considered a major risk 
factor for idiopathic VTE and its recurrence.4,5 Since the first 
report of a mutation in the SERPINC1 gene in a family with 
antithrombin (AT) deficiency, other resulting genetic defects 
have been identified including factor V Leiden, prothrombin 
G20210A mutation, protein C (PC) deficiency, protein S 
(PS) deficiency, and plasminogen (PLG) deficiency. The 
prevalence of HT varies among different ethnic groups. Fac-
tor V Leiden and G20210A mutations are almost exclusive-
ly observed in Caucasian populations, while deficiencies of 
natural anticoagulants have greater implications in Asian 
populations.6-11 The relative risks for VTE in its various 
forms of HT are also different.12 A recent study showed that 
the relative risk for recurrence of VTE was significantly 
higher in patients with PC, PS, or AT deficiency than in pa-
tients with factor V Leiden or G20210A mutation.5 Howev-
er, there is limited data on the prevalence and clinical impli-
cations of HT in VTE in Korea and in other parts of Asia.
Table 1. Acquired Risk Factors in Patients with Provoked 
Pulmonary Embolism
Acquired risk factors  Frequency,* 
n (%)
Recent surgery  31 (40.3)
Immobilization, long trip (>4 hours) 27 (35.1)
Trauma  12 (15.6)
Arterial disease  12 (15.6)
SLE, Behcet’s disease, antiphospholipid 
  antibody syndrome
†  6 (7.8)
Pregnancy, postpartum (<2 months), oral 
  contraceptive, hormone replacement therapy  5 (6.5)
COPD  4 (5.2)
Acute infection  4 (5.2)
Congestive heart failure  3 (3.9)
Chronic renal failure  2 (2.6)
Central venous catheter 2 (2.6)
SLE, systemic lupus erythematosus; COPD, chronic obstructive pulmonary 
disease.
*Frequency was counted in multiple response data.
†Diagnosed by revised classification criteria for the antiphospholipid anti-
body syndrome.
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proportion of males to females was highest in the iPE/HT+ 
group (71.4%) and lowest in the pPE group (29.9%) (p< 
0.001). The mean age at the time of diagnosis of PE was sig-
nificantly different among three groups, with the ages of 
44±14 years in the iPE/HT+ group, 54±17 years in the iPE/
HT- group, and 61±18 years in the pPE group (p<0.001). At 
the time of PE diagnosis there were no significant differenc-
es in the mean systolic blood pressure, mean heart rate, or 
the frequency of desaturation, defined by oxygen saturation 
less than 90%. There were no significant differences in the 
proportion of patients with comorbid diabetes or in regards to 
PLG on coagulation tests. Genomic DNA was isolated 
from peripheral blood leukocytes using the Wizard Genom-
ic DNA Purification Kit (Promega, Madison, WI, USA). 
All exons of the PROC, PROS1, SERPINC1, and PLG 
genes and their flanking intron regions were amplified us-
ing polymerase chain reaction for PC, PS, AT and PLG de-
ficiencies, respectively. Cyclic sequencing was performed 
using the BigDye Terminator Cycle Sequencing Ready Re-
action Kit (Applied Biosystems, Foster City, CA, USA). 
When no point mutation was identified on direct sequenc-
ing, copy number variations were additionally tested by 
employing the multiplex ligation-dependent probe amplifi-
cation (MLPA) method, as previously described.14
Statistical analyses
Comparisons of categorical variables were conducted using 
Chi-square and Fisher’s exact tests, where appropriate. Dif-
ferences in continuous variables were evaluated using uni-
variate analysis of variance. p values less than 0.05 were 
considered statistically significant. All analyses were per-
formed using SPSS software version 13.0 (SPSS Inc., Chi-
cago, IL, USA).
RESULTS
 
Study patients
A total of 161 consecutive and unrelated Korean patients 
with PE were included for analysis. Characteristics of the 
study patients are summarized in Table 2. Seventy-five pa-
tients (46.6%) were male and 86 patients (53.4%) were fe-
male. Their age at the time of diagnosis of PE ranged from 
13 to 88 years (mean age, 58 years). Eighty-four patients 
(52.2%) had iPE (52 men and 32 women; mean age, 54 
years; age range, 13 to 87 years), and 77 patients (47.8%) 
had pPE (23 men and 54 women; mean age, 61; age range, 
13 to 88 years).
Prevalence of HT and clinical characteristics of iPE 
with HT
Coagulation tests for thrombophilia were performed in 54 
of 84 patients with iPE (64.3%) (Fig. 1). Twenty eight pa-
tients (51.9%; 28/54) were diagnosed as having HT (PC, 
PS, AT, or PLG deficiency), and 26 patients (48.1%; 26/54) 
were shown to have no evidence of HT. 
We compared the clinical characteristics among patients 
in the iPE/HT+, iPE/HT-, and pPE groups (Table 3). The 
Table 2. Characteristics of Korean Patients with Pulmonary 
Embolism without Malignancy 
Characteristics n=161
Age, mean±SD (yrs) 58±18
Men, n (%) 75 (46.6)
Idiopathic PE, n (%) 84 (52.2)
Diabetes mellitus, n (%) 21 (13.0)
Hypertension, n (%) 47 (29.2)
Current smoker, n (%) 22 (13.7)
BMI, mean±SD (kg m
-2) 24.3±4.3
Previous VTE, n (%) 40 (24.8)
Concurrent DVT, n (%) 84 (52.2)
Adverse outcome,* n (%) 33 (20.5)
PE, pulmonary embolism; BMI, body mass index; VTE, venous thromboem-
bolism; DVT, deep vein thrombosis.
*Adverse outcome included death; cardiopulmonary resuscitation; throm-
bolysis; surgical embolectomy; and use of percutaneous cardiopulmonary 
support, inotropes, or mechanical ventilation.
Fig. 1. Flow diagram of the study population showing the number of pa-
tients with each diagnosis. PE, pulmonary embolism; HT, hereditary throm-
bophilia; PC, protein C; PS, protein S; AT, antithrombin; PLG, plasminogen.
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[iPE/HT+]Mirae Lee, et al.
Yonsei Med J   http://www.eymj.org   Volume 53   Number 3   May 2012 574
pPE group (20.4%) (p<0.001).
Coagulation defects and causative mutations of HT
The coagulation defects and clinical characteristics in the 
28 patients in the iPE/HT+ group are shown in Table 4. 
Sixteen patients had PC deficiency, six had PS deficiency, 
three had AT deficiency, and three had PLG deficiency 
(29.6%, 11.1%, 5.5%, and 5.5% in 54 patients with iPE, re-
spectively). Although statistical significance could not be 
assessed due to the limited number of patients with each 
coagulation defect, those with AT deficiency had the young-
est mean age at diagnosis (39±2 years) and the highest fre-
quency of adverse outcomes (100%). Of note, personal his-
the mean body mass index. Hypertension was observed most 
frequently in patients with pPE. The presence of previous 
history of VTE was observed most frequently in the iPE/
HT+ group (64.3%), followed by those of the iPE/HT- (28%) 
and the pPE group (10.4%) (p<0.001). The frequencies of 
concurrent DVT were also significantly different among the 
groups, with 75.0% in the iPE/HT+ group, 65.4% in the iPE/
HT- group, and 46.8% in the pPE group (p=0.021). Hospital 
stay was longest in the pPE group (27±30, p=0.001). Al-
though there were no significant differences in regards to in-
hospital deaths among the groups, adverse clinical outcomes 
were observed most frequently in the iPE/HT+ group 
(42.9%), followed by the iPE/HT- group (38.5%) and the 
Table 3. Comparison of the Clinical Characteristics of Patients with Idiopathic Pulmonary Embolism with Hereditary Thrombo-
philia (iPE/HT+) or without Hereditary Thrombophilia (iPE/HT-) and Provoked Pulmonary Embolism (pPE)
Characteristics iPE/HT+ (n=28) iPE/HT- (n=26) pPE (n=77) p value
Male sex, n (%) 20 (71.4) 15 (57.7) 23 (29.9) <0.001
Age, mean±SD (yrs)   44±14   54±17   61±18 <0.001
SBP, mean±SD (mm Hg) 125±17 117±14 122±26   0.372
HR, mean±SD (bpm)   85±18   87±18   86±16   0.847
Saturation <90%, n (%) 1 (3.6) 2 (7.7) 13 (16.9)   0.135
DM, n (%) 2 (7.1) 2 (7.7) 16 (20.8)   0.111
HTN, n (%)   4 (14.3)   6 (23.1) 29 (37.7)   0.048
BMI, mean±SD (kg m
-2) 24.9±2.7 25.3±5.4 24.9±4.6   0.496
Previous VTE, n (%) 18 (64.3)   7 (28.0) 8 (10.4) <0.001
DVT (+), n (%) 21 (75.0) 17 (65.4) 36 (46.8)   0.021
Hospital days, mean±SD 12±7   8±4   27±30   0.001
Adverse outcome,* n (%) 12 (42.9) 10 (38.5)   8 (20.4) <0.001
In-hospital death, n (%) 1 (3.6) 0 (0) 4 (3.8)   0.488
SBP, systolic blood pressure; HR, heart rate; DM, diabetes mellitus; HTN, hypertension; BMI, body mass index; VTE, venous thromboembolism; DVT, deep 
vein thrombosis.
*Adverse outcome included death; cardiopulmonary resuscitation; thrombolysis; surgical embolectomy; and use of percutaneous cardiopulmonary support, 
inotropes, or mechanical ventilation.
Table 4. Clinical and Laboratory Characteristics of 28 Patients with Hereditary Thrombophilia and Idiopathic Pulmonary Embolism
PC deficiency PS deficiency AT deficiency PLG deficiency
Patients, n (%) 16 (29.6) 6 (11.1) 3 (5.5) 3 (5.5)
Age, mean±SD (yrs) 40±14 50±15 39±2 56±18
Sex (men), n (%) 13 (81.3) 3 (50.0)   3 (100.0) 2 (66.7)
DVT (+), n (%) 13 (81.3) 4 (66.7) 2 (66.7) 2 (66.7)
Previous VTE, n (%) 10 (62.5) 4 (66.7) 2 (66.7) 2 (66.7)
Family history of VTE, n (%)   5 (31.2) 2 (33.3) 1 (33.3) 1 (33.3)
Adverse outcome,* n (%)   6 (37.5) 1 (16.7)   3 (100.0) 2 (66.7)
Level of deficient anticoagulant, %
†   
  (normal range, %)
‡
47±10 
(80-161)
26±12 
(50-130)
44±14 
(83-123)
50±11 
(75-112)
AT, antithrombin; PC, protein C; PS, protein S; PLG, plasminogen; DVT, deep vein thrombosis, VTE, venous thromboembolism.
*Adverse outcomes included death, cardiopulmonary resuscitation, thrombolysis, surgical embolectomy and use of percutaneous cardiopulmonary sup-
port, inotropes, and mechanical ventilation.
†Mean±SD for each protein C, protein S, antithrombin, and plasminogen. 
‡Normal range of each anticoagulant from our institutional criteria.Hereditary Thrombophilia in Pulmonary Embolism
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recurrent DVT showed similar results with our study, pre-
senting that a decrease of at least one of PC, PS, and AT 
levels was observed in almost 50% (15/34) of patients.18
We compared the clinical features of the iPE/HT+ group 
with those of the iPE/HT- and pPE groups. The iPE/HT+ 
group had significantly different features, including the 
youngest age at the time of diagnosis, the highest propor-
tion of male patients, and the highest frequencies of previ-
ous history of VTE and concurrent DVT. Interestingly, the 
age at diagnosis of PE in the iPE/HT- group was between 
those of the iPE/HT+ and pPE groups (44 years in iPE/
HT+, 54 years in iPE/HT-, and 61 years in pPE). These 
findings suggest that patients with iPE/HT- might have oc-
cult predisposition to PE, potentially caused by different ge-
netic backgrounds with a lower risk for thrombosis than 
natural anticoagulant deficiencies. A Japanese study on pa-
tients with DVT showed a similar difference in the ages be-
tween carriers and non-carriers of mutations causing natu-
ral anticoagulant deficiencies as 44.7 years and 52.6 years, 
respectively.8 The male predominance in the iPE/HT+ group 
(71%) was also a notable finding, considering the autoso-
mal dominant inheritance of natural anticoagulant deficien-
cies and the similar incidences of initial VTE among men 
and women.19 The gender difference in the prevalence of 
VTE combined with HT is not well known. The risk of re-
current VTE in men and women, however, was investigat-
ed in several studies, and similar conclusions that the risk 
tory and family history of VTE were similar among the 
four groups.
Molecular genetic tests were performed in 14 of 28 pa-
tients with HT, and the causative mutation was identified in 
13 patients (Table 5). Seven patients had a mutation in the 
PROC gene, three had a mutation in the PROS1 gene, two 
had a mutation in the SERPINC1 gene, and one had a mu-
tation in the PLG gene. The mean age of the 13 patients 
with genetically confirmed HT was 43±12 years, and the 
majority (83%) of them was men. Eight patients (66%) had 
a previous history of VTE, with a mean age of 39±16 years 
at first onset of VTE.
DISCUSSION
In this study, we found a high prevalence of HT in Korean 
patients with idiopathic PE. Up to 52% of patients with iPE 
had PC, PS, AT, or PLG deficiency. Other recent studies in 
Asian countries reported that the prevalence of HT in all-
cause DVT were 28.3% and 32.1% in Japan and Taiwan, 
respectively.15,16 Although the prevalence of HT in idiopath-
ic VTE was not known well, a study reported that 67% of 
patients with idiopathic DVT had one positive marker for 
thrombophilia including factor V Leiden and prothrombin 
mutations as well as PC, PS, and AT deficiencies.17 Another 
study performed in young patients (aged <40 years) with 
Table 5. Clinical Characteristics and Results of Genetic Tests of Patients with Genetically Confirmed Hereditary Thrombophilia
Patient* Age Sex VTE history Type of 
previous VTE
First-onset 
age
† Gene mutation Predicted amino 
acid change
PC_1 50 M Yes DVT 49 PROC p.Arg211Trp
PC_2 32 M No - 32 PROC p.Arg211Trp
PC_3 25 M Yes DVT 24 PROC p.Met406Ile
PC_4 43 M No - 43 PROC p.Met406Ile
PC_5 33 M Yes PE, DVT 32 PROC p.Met406Ile
PC_6 49 M Yes DVT 49 PROC p.Ala240GlyfsX18
‡
PC_7 43 M No - 43 PROC p.Met406Ile
PS_1 53 F No - 53 PROS1 p.Gln572X
‡
PS_2 46 M Yes DVT 24 PROS1 (Del. Exon 2)
§
PS_3 39 M Yes PE, DVT 27 PROS1 p.Tyr636Cys
AT_1 37 M Yes DVT 35 SERPINC1 p.Trp81X
‡
AT_2 40 M No - 40 SERPINC1 p.Arg425His
PLG_1 73 F Yes PE 69 PLG p.Ala620Thr
Total  (13) 43±12 85% (men) 62% (yes) 40±13
VTE, venous thromboembolism; DVT, deep vein thrombosis; PE, pulmonary embolism; AT, antithrombin; PC, protein C; PS, protein S; PLG, plasminogen.
*Patients were labeled randomly with abbreviation of their deficient protein.
†First-onset age of VTE in each patient.
‡Novel mutation.
§By multiplex ligation-dependent probe amplification analyses.Mirae Lee, et al.
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previously reported in Korean male patients with VTE, and 
Met406Ile was described as a novel mutation.25 Given the 
findings from the present study, we speculate that Arg-
211Trp and Met406Ile are frequent mutations causing PC 
deficiency in Koreans. The remaining mutation of the 
PROC gene was a novel frame shift mutation (Ala240Glyf-
sX18 in PC_6 of Table 5). Among the three patients with 
PS deficiency, one patient (33.3%) had a large copy number 
variation detected via MLPA analyses (PS_2 of Table 5). 
This result is in line with a recent series of reports indicating 
that large copy number variations are uncommonly ob-
served in PS deficiency.13,26,27 The other two mutations of the 
PROS1 gene were a novel nonsense mutation (Gln572X) 
and a known missense mutation (Tyr636Cys). One of the 
two mutations in SERPINC1, Trp81X in AT-1, was a novel 
mutation, and the Ala620Thr mutation in PLG has been 
previously reported in Korean patients with DVT.28 
This study had several limitations. First, thrombotic pro-
files tests were not performed in most patients in the pro-
voked PE group. Patients in the provoked group were not 
tested because most patients in this group had evident risk 
factors and were relatively old. Therefore, they were un-
likely to have HT. Second, as mentioned, about one third of 
the patients with idiopathic PE were not tested for the pres-
ence of HT. Finally, as our analysis was performed retro-
spectively, there is a chance that personal history or family 
history for VTE was more enthusiastically detailed in the 
idiopathic PE group, especially in patients with HT, than 
provoked PE group.
In conclusion, the present study investigated the preva-
lence of HT in Korean patients with iPE and revealed that 
about half of the study patients had a natural anticoagulant 
deficiency or PLG deficiency. Patients with iPE and HT 
were mostly young male patients with concurrent DVT, a 
history of VTE, and a higher frequency of adverse clinical 
outcomes. Protein C deficiency was the most common ge-
netic defect with recurrent missense mutations. Therefore, 
it is reasonable to conclude that Korean patients with iPE 
should be tested for having HT. To investigate the precise 
prevalence and clinical characteristics of HT in Korean pa-
tients with iPE, large-scale prospective study is needed.
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was higher in men than in women were drawn.20-22 Baglin, 
et al.20 reported that the recurrence risk was higher in men 
than in women when only patients with idiopathic VTE 
were analyzed. Our study showed a higher frequency of fe-
male patients in the pPE group. This finding was consid-
ered to be due to the fact that orthopedic surgery, connec-
tive tissue disease, and pregnancy-related conditions were 
major risk factors of PE in this study. Our data also showed 
a higher frequency of concurrent DVT in iPE than in pPE, 
which is in line with a recent study that showed iPE was 
more frequent than pPE in PE with DVT than in PE with-
out DVT.23 In addition, the same study showed that natural 
anticoagulant deficiency was observed more commonly in 
PE with DVT than in PE without DVT. Lastly, the highest 
frequency of adverse outcomes was observed in the iPE/
HT+ group in this study, suggesting poor prognostic impli-
cations of PE in the setting of HT.
It is known that the relative risks for the development and 
recurrence of thrombosis differ among the different genetic 
defects implicated in HT.12,24 A recent study in the Nether-
lands showed that the absolute thrombotic risks in patients 
with PC, PS, or AT deficiency were much higher than those 
in patients with factor V Leiden or prothrombin 20210A.12 
This finding, along with the prevalence of anticoagulant de-
ficiencies seen in the present study and in other studies 
from Asian countries,15,16 indicates that tests for HT and risk 
stratification according to the presence of HT are important 
in Asian patients with VTE. A study in Taiwan demonstrat-
ed that thrombotic risks for PC or PS deficiency are higher 
than those for AT deficiency or PLG deficiency.9 When we 
compared the clinical characteristics among four coagula-
tion defects underlying HT, there were differences in the 
mean age at diagnosis and the frequency of adverse out-
comes. Due to the small number of patients, however, the 
significance of these findings remains indeterminate.
Since coagulation test results are susceptible to underly-
ing disease and anticoagulation, molecular genetic studies 
provided definitive evidence of HT. Considering this limita-
tion a recent study in Japan investigated the prevalence of 
natural anticoagulant deficiency in patients with DVT using 
only genetic tests.8 Their results showed that 55 (32%) of 
173 patients carried a genetic defect in one of the PROC, 
PROS1, or SERPINC1 genes. In our study, the coagulation 
defect was confirmed using molecular genetic tests in 13 
patients in the iPE/HT+ group. Most patients with PROC 
mutations (85.7%; 6/7) had a missense mutation, either 
with Arg211Trp or Met406Ile. Both of the mutations were Hereditary Thrombophilia in Pulmonary Embolism
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